Cardiff Oncology CRDF Stock
Cardiff Oncology Price Chart
Cardiff Oncology CRDF Financial and Trading Overview
| Cardiff Oncology stock price | 4.36 USD |
| Previous Close | 1.59 USD |
| Open | 1.59 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1400 |
| Day's Range | 1.56 - 1.59 USD |
| 52 Week Range | 1.2 - 3.41 USD |
| Volume | 54.79K USD |
| Avg. Volume | 173.76K USD |
| Market Cap | 71.04M USD |
| Beta (5Y Monthly) | 1.754577 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.93 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8 USD |
CRDF Valuation Measures
| Enterprise Value | -23354302 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.152174 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 179.83987 |
| Price/Book (mrq) | 0.7361111 |
| Enterprise Value/Revenue | -59.125 |
| Enterprise Value/EBITDA | 0.575 |
Trading Information
Cardiff Oncology Stock Price History
| Beta (5Y Monthly) | 1.754577 |
| 52-Week Change | -5.91% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.41 USD |
| 52 Week Low | 1.2 USD |
| 50-Day Moving Average | 1.64 USD |
| 200-Day Moving Average | 1.65 USD |
CRDF Share Statistics
| Avg. Volume (3 month) | 173.76K USD |
| Avg. Daily Volume (10-Days) | 120.99K USD |
| Shares Outstanding | 44.68M |
| Float | 41.33M |
| Short Ratio | 3.48 |
| % Held by Insiders | 7.33% |
| % Held by Institutions | 23.62% |
| Shares Short | 540.99K |
| Short % of Float | 1.25% |
| Short % of Shares Outstanding | 1.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -10349.36% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -20.79% |
| Return on Equity (ttm) | -34.36% |
Income Statement
| Revenue (ttm) | 395K USD |
| Revenue Per Share (ttm) | 0.009 USD |
| Quarterly Revenue Growth (yoy) | 12.19% |
| Gross Profit (ttm) | -26721000 USD |
| EBITDA | -40585000 USD |
| Net Income Avi to Common (ttm) | -38958000 USD |
| Diluted EPS (ttm) | -0.88 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 96.97M USD |
| Total Cash Per Share (mrq) | 2.17 USD |
| Total Debt (mrq) | 2.58M USD |
| Total Debt/Equity (mrq) | 2.67 USD |
| Current Ratio (mrq) | 12.488 |
| Book Value Per Share (mrq) | 2.16 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -32230000 USD |
| Levered Free Cash Flow (ttm) | -18801000 USD |
Profile of Cardiff Oncology
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 11055 Flintkote Avenue |
| ZIP | 92121 |
| Phone | 858 952 7570 |
| Website | https://www.cardiffoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 25 |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Q&A For Cardiff Oncology Stock
What is a current CRDF stock price?
Cardiff Oncology CRDF stock price today per share is 4.36 USD.
How to purchase Cardiff Oncology stock?
You can buy CRDF shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cardiff Oncology?
The stock symbol or ticker of Cardiff Oncology is CRDF.
Which industry does the Cardiff Oncology company belong to?
The Cardiff Oncology industry is Biotechnology.
How many shares does Cardiff Oncology have in circulation?
The max supply of Cardiff Oncology shares is 57.49M.
What is Cardiff Oncology Price to Earnings Ratio (PE Ratio)?
Cardiff Oncology PE Ratio is now.
What was Cardiff Oncology earnings per share over the trailing 12 months (TTM)?
Cardiff Oncology EPS is -0.93 USD over the trailing 12 months.
Which sector does the Cardiff Oncology company belong to?
The Cardiff Oncology sector is Healthcare.
Cardiff Oncology CRDF included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}